ALEXANDRITE LASER FOR PDT CANCER RESEARCH

我们的目标是制定一个更有效的方法， 光动力疗法（PDT）的癌症，通过结合两个 新兴技术：a）具有改进的 在深红色中操作的光化学特性 身体组织最半透明的波长区域，以及B） 一种上级波长可调谐固态紫翠宝石激光器 在这个光谱区域的激光源。 其中，新 光敏剂为绿素2、紫素3、菌绿素4、硅 萘酞菁5、6、7和细菌脱镁叶绿酸8， 分别在xxxx、715nm、765nm和755nm处的吸收。 虽然新兴技术，实验室紫翠宝石激光器， 在脉冲模式下从710 nm到800 nm连续可调 740 nm到800 nm是连续模式， 性能符合应用程序要求， 适用于光纤传输。 第一阶段的目标 是适当配置的翠绿宝石激光器的构造， PDT实验，以及该激光器的测试和评估 使用verdins和其它合适的光敏剂， 实验室大鼠通过建立的方法。 结果将指导 激光器、光束传输装置的进一步发展， 治疗方案，潜在地导致成本效益 PDT的临床激光。

Our objectives is to develop a more effective approach to photodynamic therapy (PDT) of cancer by combining two emergent technologies: a) New photosensitizers with improved photochemical characteristics which operate in the deep red wavelength region where body tissue is most translucent, and b) The alexandrite laser1, a superior wavelength tunable solid state laser source in this spectral region. Included among these new photosensitizers are verdins2, purpurins3, bacteriochlorin4, silicon naphthalocyanine5,6,7 and bacteriopheophorbide8, with peak absorption, respectively, at xxxx, 715nm, 765nm, and 755nm. While an emergent technology, laboratory alexandrite lasers, continuously tunable from 710nm to over 800nm in pulsed mode and 740nm to 800nm is continuous mode, have demonstrated performance will within application requirements, and are well adapted to fiber optic delivery. The objectives of this first phase are the construction of a suitably configured alexandrite laser for PDT experimentation, and the test and evaluation of this laser with the verdins and other appropriate photosensitizers using laboratory rats by established methods. The results will guide further development of the laser, beam delivery apparatus and treatment protocol, leading, potentially, to a cost effective clinical laser for PDT.